{"id":"https://genegraph.clinicalgenome.org/r/1b1e968c-59b9-4ae7-8f5c-6d15328a4312v1.0","type":"EvidenceStrengthAssertion","dc:description":"The *GUCY2D* gene was first reported in relation to autosomal recessive cases of Leber congenital amaurosis in 1996 (Perrault et al., PMID: 8944027). Affected individuals have since been identified in a number of other publications (PMID: 16505055, PMID: 29559409, PMID: 23035049), with causal biallelic variants in *GUCY2D* specifically diagnostic for either Leber congenital amaurosis 1 (more severe) or congenital stationary night blindness type 1I (milder and later onset). Both disease entities are completely penetrant, however, patients diagnosed with Leber congenital amaurosis 1 present with severe visual impairment before the age of 5 (usually during the first year of life) while their counterparts with congenital stationary night blindness type 1I are diagnosed between the ages of 9 and 45, presenting with night blindness since childhood and gradual progression to mild retinal dystrophy (PMID: 29559409). Patients with Leber congenital amaurosis 1 also exhibit other eye-specific features, including nystagmus, photophobia, strabismus, eye poking, keratoconus, attenuation of retinal blood vessels, optic disc pallor, and mild retinal pigment epithelium mottling, often with a relatively normal appearance to the fundus. Patients with congenital stationary night blindness type 1I exhibit only a subset of these features, including attenuation of retinal blood vessels and progressive visual field constriction. Electroretinogram (ERG) response is nondetectable in Leber congenital amaurosis 1 patients, however, those with congenital stationary night blindness type 1I initially exhibit nondetectable responses only in rod-based ERG, while cone-based ERG responses may remain normal until the third decade of life or later. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found the molecular mechanism (biallelic loss of function in the GUCY2D gene product) and mode of inheritance (autosomal recessive) to be consistent among unrelated patients diagnosed with either Leber congenital amaurosis 1 or congenital stationary night blindness type 1I, while the phenotypic variability between them appeared to represent a spectrum of disease rather than separate disease entities. Therefore, cases of Leber congenital amaurosis 1 or congenital stationary night blindness type 1I have been lumped into a single disease entity, referred to as *GUCY2D*-related recessive retinopathy (MONDO:0100453). Two additional disease entities, cone-rod dystrophy 6 and central areolar choroidal dystrophy 1, were asserted in relation to monoallelic variants in *GUCY2D*, particularly those located in the dimerization domain (PMID: 11115851, PMID: 11709018, PMID: 29061346). While these disease entities are characterized by similar phenotypes, their different mode of inheritance and unique variants suggested a different mechanism of pathogenesis. Thus, *GUCY2D* was separately curated for its relationship to this disease entity, referred to as *GUCY2D*-related dominant retinopathy (MONDO:0100441).\n\nEight suspected pathogenic variants were scored as part of this curation (two nonsense, one frameshift, and five missense), which have been collectively reported in twelve probands in three publications (PMID: 8944027, PMID: 16505055, PMID: 29559409). Eight probands were homozygous for their respective variants (PMID: 8944027, PMID: 16505055), and five were reported to have consanguineous parents (PMID: 8944027, PMID: 16505055). The four other probands were compound heterozygotes within the *GUCY2D* locus (PMID: 16505055, PMID: 29559409). Two families with segregation evidence were available in these publications (PMID: 8944027), and contributed to the scoring of the gene-disease relationship. More case-level data was available (PMID: 23035049, PMID: 29559409), but was not scored as part of this curation as the maximum scoring for this evidence type had already been reached.\n\nThis gene-disease relationship has not been studied in case-control studies at the single variant level or aggregate variant level.\n\nThe mechanism of pathogenicity appears to be biallelic loss of function, characterized in some cases by frameshift or nonsense variants predicted to trigger a decrease in the amount of the gene product (PMID: 8944027, PMID: 29559409). All probands found for this curation harbored two variant alleles within the *GUCY2D* locus.\n\nThis gene-disease association is also supported by experimental evidence that *GUCY2D* expression is dramatically higher in the retina relative to control tissues (PMID: 30239781), particularly along the retinal outer nuclear layer (PMID: 1356371). Proper subcellular localization of GUCY2D protein requires its C-terminus to physically interact with the RD3 protein, which is encoded by a gene that harbors causal variants for Leber congenital amaurosis 12 (PMID: 21078983). Biochemical studies have demonstrated that *GUCY2D* encodes a receptor guanylyl cyclase that catalyzes cGMP production as part of the recovery of the dark state following visual excitation (PMID: 1356371). This helps explain why chickens homozygous for a null variant of the *GUCY2D* ortholog exhibit dramatically reduced cGMP levels within the retina, nondetectable ERG responses from rod and cone photoreceptors, early onset blindness, and optokinetic reflex abnormalities analogous to nystagmus (PMID: 9448321). Similarly, mice with homozygous knockout of *Gucy2e* (the murine *GUCY2D* ortholog) exhibit degeneration and loss of cone photoreceptor cells in the outer nuclear layer, nondetectable cone-based ERG responses, reduced amplitude of rod-based ERG responses, and loss of visual acuity (PMID: 10407028, PMID: 17255100, PMID: 21671801). Rod photoreceptor function has been shown to be relatively preserved in these mice due to their dependence on a gene paralog (PMID: 17255100). These mouse phenotypes can be partially rescued by injection of adeno-associated virus (AAV) delivering wild-type human *GUCY2D* or mouse *Gucy2e*.\n\nIn summary, *GUCY2D* is definitively associated with *GUCY2D*-related recessive retinopathy. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a definitive classification.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1b1e968c-59b9-4ae7-8f5c-6d15328a4312","GCISnapshot":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2022-03-27T23:22:10.761Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2022-03-27T23:22:23.362Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a998f954-0559-4471-a22f-c23c66ef075a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76d12b78-0dc6-49d4-a13c-5d48e3d7d854","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76d12b78-0dc6-49d4-a13c-5d48e3d7d854_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/76d12b78-0dc6-49d4-a13c-5d48e3d7d854_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226054"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a998f954-0559-4471-a22f-c23c66ef075a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","rdfs:label":"Perrault_1996_Family_9_Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by Sanger sequencing of PCR products from the GUCY2D locus.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/76d12b78-0dc6-49d4-a13c-5d48e3d7d854_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/aaef27db-8b83-48b7-ac4e-2fff6d2bbe0a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9318b074-c868-411b-bbad-d22338fb7327","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity. Since one such proband has already been up-scored at full strength, this individual has been up-scored at only half strength.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9318b074-c868-411b-bbad-d22338fb7327_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9318b074-c868-411b-bbad-d22338fb7327_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/aaef27db-8b83-48b7-ac4e-2fff6d2bbe0a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","rdfs:label":"Perrault_1996_Family_11_Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by Sanger sequencing of PCR products from the GUCY2D locus.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9318b074-c868-411b-bbad-d22338fb7327_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/962f40cc-86fa-4d77-9b9a-101e6972065e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17bf7348-ad38-420a-ac1a-a8d5e20cf161","type":"EvidenceLine","dc:description":"Evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.2281C>T (p.p.Arg761Trp) variant is limited to computational prediction.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17bf7348-ad38-420a-ac1a-a8d5e20cf161_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409","allele":{"id":"https://genegraph.clinicalgenome.org/r/e4fad3d3-36da-46de-9339-fabef65b5cef","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2281C>T (p.Arg761Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/854601"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3e9ec7cf-4a98-487d-a693-2c8ac72e5702","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e9ec7cf-4a98-487d-a693-2c8ac72e5702_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3e9ec7cf-4a98-487d-a693-2c8ac72e5702_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409","allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226075"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/962f40cc-86fa-4d77-9b9a-101e6972065e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409","rdfs:label":"Stunkel_2018_Patient_5","allele":[{"id":"https://genegraph.clinicalgenome.org/r/e4fad3d3-36da-46de-9339-fabef65b5cef"},{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"}],"detectionMethod":"Patient 5 was tested for known LCA-causing variants using an allele-specific method, leading to the detection of 2 variants in GUCY2D.","firstTestingMethod":"Other","phenotypeFreeText":"Refractive error was minimal. Progression of nyctalopia was noticed at 44 years of age. Rod-based ERG was not detectable at age 52.","phenotypes":["obo:HP_0030469","obo:HP_0000552","obo:HP_0000662","obo:HP_0008043","obo:HP_0001133","obo:HP_0000539","obo:HP_0008275","obo:HP_0007737","obo:HP_0011463"],"previousTesting":false,"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/17bf7348-ad38-420a-ac1a-a8d5e20cf161_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/3e9ec7cf-4a98-487d-a693-2c8ac72e5702_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.35},{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61123bcf-dfb2-43ff-91d7-318b0d4f4b77_proband_segregation","type":"FamilyCosegregation","dc:description":"The family meets the minimum number of affected individuals required for incorporation in the eLOD calculation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","rdfs:label":"Perrault_1996_Family_11","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/61123bcf-dfb2-43ff-91d7-318b0d4f4b77","type":"Family","rdfs:label":"Perrault_1996_Family_11","member":{"id":"https://genegraph.clinicalgenome.org/r/aaef27db-8b83-48b7-ac4e-2fff6d2bbe0a"}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/aaef27db-8b83-48b7-ac4e-2fff6d2bbe0a"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/fc56398f-ee66-46d2-bab0-fbd949ad3775_proband_segregation","type":"FamilyCosegregation","dc:description":"The number of segregations (3) is sufficient to incorporate this data into the eLOD score calculation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","rdfs:label":"Perrault_1996_Family_9","estimatedLodScore":2.06,"family":{"id":"https://genegraph.clinicalgenome.org/r/fc56398f-ee66-46d2-bab0-fbd949ad3775","type":"Family","rdfs:label":"Perrault_1996_Family_9","member":{"id":"https://genegraph.clinicalgenome.org/r/a998f954-0559-4471-a22f-c23c66ef075a"}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Affected family members are described as having Leber congenital amaurosis.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/a998f954-0559-4471-a22f-c23c66ef075a"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/b2f36751-a63e-4a43-91e1-f1da154ec6ac_family_segregation","type":"FamilyCosegregation","dc:description":"Genotyping was performed by linkage mapping alone. Maximum LOD score was associated with the D17S1353 marker, with theta = 0.13. Eight out of eighteen families exhibited linkage to chromosome 17.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8641699","rdfs:label":"Camuzat_1996_Familes_2_3_9_11_12_15_17_18","estimatedLodScore":13.39,"family":{"id":"https://genegraph.clinicalgenome.org/r/b2f36751-a63e-4a43-91e1-f1da154ec6ac","type":"Family","rdfs:label":"Camuzat_1996_Familes_2_3_9_11_12_15_17_18"},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":6,"phenotypePositiveAllelePositive":22,"publishedLodScore":5.78}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ec5c1999-1393-4540-936f-5e8fd5b9c801_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ac19731-52d8-427f-af09-f6022c94dd98","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ac19731-52d8-427f-af09-f6022c94dd98_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4ac19731-52d8-427f-af09-f6022c94dd98_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ec5c1999-1393-4540-936f-5e8fd5b9c801","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","rdfs:label":"Yzer_2006_Patient_22018","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. No perception of light was detected at age 2.5 years. Pupils were wide and minimally responsive to bright light.","phenotypes":["obo:HP_0003593","obo:HP_0000550","obo:HP_0001483","obo:HP_0002457","obo:HP_0000639","obo:HP_0000543","obo:HP_0030553"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4ac19731-52d8-427f-af09-f6022c94dd98_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a55ae610-e783-48d4-b43d-8238bf063012_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c59d53c2-449b-40d4-9549-6323b8ee56f8","type":"EvidenceLine","dc:description":"The variant has been up-scored to reflect the functional evidence of its detrimental effect on GUCY2D activity, as well as its recurrence in multiple affected probands from apparently unrelated families.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c59d53c2-449b-40d4-9549-6323b8ee56f8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c59d53c2-449b-40d4-9549-6323b8ee56f8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/6575113d-3cf1-4fbe-a7d0-8811f28c8de5","type":"EvidenceLine","dc:description":"The variant has been up-scored to reflect the functional evidence of its detrimental effect on GUCY2D activity, as well as its recurrence in multiple affected probands from apparently unrelated families. Up-scoring was limited since the same variant has already been up-scored for recurrence at full strength in a separate proband.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6575113d-3cf1-4fbe-a7d0-8811f28c8de5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6575113d-3cf1-4fbe-a7d0-8811f28c8de5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/a55ae610-e783-48d4-b43d-8238bf063012","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","rdfs:label":"Yzer_2006_Patient_441","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":3,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"}],"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exons of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Age was 15 months at time of last evaluation.","phenotypes":["obo:HP_0007663","obo:HP_0000550","obo:HP_0000662","obo:HP_0001483","obo:HP_0003593","obo:HP_0000639"],"previousTesting":true,"previousTestingDescription":"An LCA-specific microarray ChIP was used for initial genotyping, using antisense oligos to screen for 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/c59d53c2-449b-40d4-9549-6323b8ee56f8_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6575113d-3cf1-4fbe-a7d0-8811f28c8de5_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/26eb9070-53de-4450-93ca-8525621d49d1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d0bc7b06-0183-493d-8dc7-4d4930d0e1da","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d0bc7b06-0183-493d-8dc7-4d4930d0e1da_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d0bc7b06-0183-493d-8dc7-4d4930d0e1da_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/26eb9070-53de-4450-93ca-8525621d49d1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","rdfs:label":"Yzer_2006_Patient_22597","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Diagnosis was made soon after birth, but an exact age is not described. Visual acuity was limited to light perception.","phenotypes":["obo:HP_0006934","obo:HP_0003593","obo:HP_0000550","obo:HP_0030532","obo:HP_0007843"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d0bc7b06-0183-493d-8dc7-4d4930d0e1da_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/04578fdf-5a3b-4281-b644-05261d03fb17_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b4c2d6e-1626-4934-8dae-43c307222226","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b4c2d6e-1626-4934-8dae-43c307222226_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6b4c2d6e-1626-4934-8dae-43c307222226_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/04578fdf-5a3b-4281-b644-05261d03fb17","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","rdfs:label":"Yzer_2006_Patient_20955","ageType":"AgeAtReport","ageUnit":"Years","ageValue":23,"allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Retinal pigment epithelium mottling in the mid- and far periphery was minimal.","phenotypes":["obo:HP_0007688","obo:HP_0007814","obo:HP_0001483","obo:HP_0008043","obo:HP_0000639","obo:HP_0007663","obo:HP_0003593","obo:HP_0000563"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6b4c2d6e-1626-4934-8dae-43c307222226_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c7b756e2-47d3-4fa7-b049-4fee703fa083_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0eb29583-49d0-4175-915c-02cbffa598ad","type":"EvidenceLine","dc:description":"Evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.247C>T (p.Arg83Cys) variant is limited to computational prediction.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0eb29583-49d0-4175-915c-02cbffa598ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409","allele":{"id":"https://genegraph.clinicalgenome.org/r/f57f359f-d590-4d31-ae88-ec01d3fb3efa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.247C>T (p.Arg83Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA397943039"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/24f3a855-c349-4b2d-ab28-d9349058908d","type":"EvidenceLine","dc:description":"NM_000180.4(GUCY2D):c.1633C>T (p.Gln545Ter) is a nonsense variant in exon 7 predicted to trigger NMD or to at least disrupt ~51% of the protein product through truncation.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24f3a855-c349-4b2d-ab28-d9349058908d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409","allele":{"id":"https://genegraph.clinicalgenome.org/r/2e44d0db-5c1c-4b21-9959-6947f1527564","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.1633C>T (p.Gln545Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/689384"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c7b756e2-47d3-4fa7-b049-4fee703fa083","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409","rdfs:label":"Stunkel_2018_Patient_2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":9,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/2e44d0db-5c1c-4b21-9959-6947f1527564"},{"id":"https://genegraph.clinicalgenome.org/r/f57f359f-d590-4d31-ae88-ec01d3fb3efa"}],"detectionMethod":"This individual was initially subjected to screening for variants in NYX, CACNA1F, RHO, or TRPM1, with negative results. Whole exome sequencing then detected 2 variants in GUCY2D.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Minor color vision errors were detected by D15 testing.","phenotypes":["obo:HP_0003621","obo:HP_0000662","obo:HP_0007987","obo:HP_0002527","obo:HP_0030329","obo:HP_0001133","obo:HP_0030474"],"previousTesting":true,"previousTestingDescription":"This individual was initially subjected to screening for variants in NYX, CACNA1F, RHO, or TRPM1, with negative results.","secondTestingMethod":"Exome sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/24f3a855-c349-4b2d-ab28-d9349058908d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0eb29583-49d0-4175-915c-02cbffa598ad_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/bea643ba-2528-467b-ac3b-a3a41691ceed_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2b4151c7-3a44-4c57-b39f-4dbece0fff14","type":"EvidenceLine","dc:description":"The variant has been down-scored due to the reported consanguinity of the family, which leaves open the possibility that other linked regions of homozygosity may contribute to the phenotype of the patient.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2b4151c7-3a44-4c57-b39f-4dbece0fff14_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","allele":{"id":"https://genegraph.clinicalgenome.org/r/c9464ea2-2c5d-4001-868c-59d10a3e8260","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.622del (p.Arg208fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226151"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/bea643ba-2528-467b-ac3b-a3a41691ceed","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","rdfs:label":"Perrault_1996_Family_12_Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/c9464ea2-2c5d-4001-868c-59d10a3e8260"},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by SSCP and by Sanger sequencing of PCR products from all 20 exons of the GUCY2D locus.","firstTestingMethod":"SSCP","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/2b4151c7-3a44-4c57-b39f-4dbece0fff14_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8a1e99f8-d9be-4c83-9592-4c141e3c9a56_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4758bc3-fcb7-469d-a935-27ae170faba7","type":"EvidenceLine","dc:description":"The variant has been down-scored due to the reported consanguinity of the family, which leaves open the possibility that other linked genomic regions of homozygosity may contribute to the phenotype.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4758bc3-fcb7-469d-a935-27ae170faba7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","allele":{"id":"https://genegraph.clinicalgenome.org/r/51b4cc52-9a8b-4e79-a8b3-6e1e9ad2e3d8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.3(GUCY2D):c.389del (p.Pro130Leufs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226143"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8a1e99f8-d9be-4c83-9592-4c141e3c9a56","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519","rdfs:label":"Perrault_1996_Family_3_Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/51b4cc52-9a8b-4e79-a8b3-6e1e9ad2e3d8"},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by SSCP and by Sanger sequencing of PCR products from all 20 exons of the GUCY2D locus.","firstTestingMethod":"SSCP","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c4758bc3-fcb7-469d-a935-27ae170faba7_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4d3b2786-a63d-45fd-8696-853140cd5642_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47d22109-0502-4fd1-a573-0f6de5f1d046","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47d22109-0502-4fd1-a573-0f6de5f1d046_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/47d22109-0502-4fd1-a573-0f6de5f1d046_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4d3b2786-a63d-45fd-8696-853140cd5642","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","rdfs:label":"Yzer_2006_Patient_21557","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"detectionMethod":" The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Bilateral cataracts were dense and prevented fundoscopy.","phenotypes":["obo:HP_0000639","obo:HP_0003593","obo:HP_0000518","obo:HP_0000563","obo:HP_0007688","obo:HP_0020049","obo:HP_0030553","obo:HP_0000618"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/47d22109-0502-4fd1-a573-0f6de5f1d046_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f63827f8-f09d-493c-8eeb-b04a210a1fb8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b768fbb-02f9-45d1-9ad7-ace608f54498","type":"EvidenceLine","dc:description":"Evidence for the pathogenicity of the NM_000180.4(GUCY2D):c.2837C>T (p.Ala946Val) variant is limited to computational predictions.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b768fbb-02f9-45d1-9ad7-ace608f54498_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/c301de03-807f-4d2e-8a40-0385c2247396","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2837C>T (p.Ala946Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226099"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/836d1846-0ad2-49d3-bbad-197ed6179f05","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/836d1846-0ad2-49d3-bbad-197ed6179f05_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/836d1846-0ad2-49d3-bbad-197ed6179f05_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","allele":{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/f63827f8-f09d-493c-8eeb-b04a210a1fb8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055","rdfs:label":"Yzer_2006_Patient_21067","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":6,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/c301de03-807f-4d2e-8a40-0385c2247396"},{"id":"https://genegraph.clinicalgenome.org/r/545d10d0-e87f-45a0-8ce3-322464c71079"}],"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from all 20 exons of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","phenotypes":["obo:HP_0012643","obo:HP_0003593","obo:HP_0000550","obo:HP_0000543","obo:HP_0000565","obo:HP_0000486","obo:HP_0000613","obo:HP_0000639","obo:HP_0007703","obo:HP_0007663","obo:HP_0012426","obo:HP_0008043"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/836d1846-0ad2-49d3-bbad-197ed6179f05_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6b768fbb-02f9-45d1-9ad7-ace608f54498_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.35}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df90bc7e-ff22-4230-824f-b3f96b3ee962","type":"EvidenceLine","dc:description":"While this paper adds phenotypic detail to an existing mouse model, scoring for this mouse has been performed for PMID: 10407028 instead.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a0154aa-cea7-4937-ab0b-60361e597eb8","type":"Finding","dc:description":"This publication confirms previously-reported ERG abnormalities of rod and especially cone photoreceptors (PMID: 10407028). The abnormal retinal morphology HPO term refers to abnormalities in the ultrastructure of the photoreceptor outer segment, which exhibited disorganization (Figures S2B, S2F, 8C, and 8E) and low GCAP1 and GCAP2 expression levels (Figures 5J and 5N), providing early signs of instability and degeneration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17255100","rdfs:label":"Updated phenotypes from homozygous Gucy2e knockout mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3d0c2d5d-9d4a-4cd6-aa71-d6b46146906b","type":"EvidenceLine","dc:description":"This model was not scored at a higher level due to the natural occurrence of the variant (necessitating an inbred background that may have other linked areas of homozygosity affecting disease severity).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b7f47b04-9778-4ddb-a744-11b2acd5d2d4","type":"Finding","dc:description":"Chickens harboring the null variant in a homozygous state have dramatically lower levels of cGMP in the retina (Figure 1) and absent expression of GC1, the GUCY2D ortholog (Figure 2). Rod and cone photoreceptor cells develop normally, but have little to no function according to ERG. This is similar to the normal fundus appearance in LCA patients, despite severe early vision loss. A related article on the same model (PMID: 16700630) establishes that the chickens harboring the null allele are also similar to human patients in that they exhibit early onset blindness and abnormal optokinetic reflex scores (a surrogate for nystagmus). The model also recapitulates the mechanism (biallelic GUCY2D loss-of-function) and mode of inheritance (homozygous state) of the human patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9448321","rdfs:label":"Homozygous disruption of the chicken ortholog of GUCY2D","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3a4797d7-3fbd-4bcd-b9e4-5ed50c6bf41f","type":"EvidenceLine","dc:description":"The mouse model recapitulates the key visual defects of the human patients. Despite the relative sparing of rod function, this has only been moderately down-scored due to evidence that these photoreceptor cells in the mouse rely on a gene paralog instead.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a7f828a-eb9f-401e-b263-c57b51fad09b","type":"Finding","dc:description":"The model system recapitulates the functional (ERG) defects of the human patients, particularly in the cone and to a lesser extent in the rod photoreceptor cells. The absence of more severe rod defects is explained by a mouse-specific expression pattern of a gene paralog. Mice and humans with loss-of-function both exhibit some defects in retinal morphology as well. By 5 weeks of age, Gucy2e-deficient animals exhibit dramatic reduction/degeneration of cones in the outer nuclear layer (Fig. 3ad). This was confirmed by disappearance of labeling of cone cell nuclei by the lectin PNA (Fig. 3g-h). ERG showed that rod a-wave and b-wave were markedly reduced by 1 month of age, while cone responses were nondetectable as early as 2 months of age (Fig. 4a-b). A proposed explanation for the absence of more severe rod defects is the continued presence of the Gucy2f paralog in this mouse model, which may compensate for the absence of Gucy2e function in rod cells specifically. This hypothesis has been confirmed in a subsequent double-knockout model (PMID: 17255100)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10407028","rdfs:label":"Phenotypes of a homozygous Gucy2e mouse knockout model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/686caad7-c84a-4c5e-b8f2-588ed6ecdd69","type":"EvidenceLine","dc:description":"Injection of the AAV-borne transgene at least partially rescues all phenotypes of interest, whether the transgene is mouse Gucy2e or human GUCY2D. Scoring has been kept at the moderate level due to the potential for overexpression effects, the design of the experiment in mice rather than in human patients, and the absence of a patient-derived variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2adf4bc-b57f-40fd-9c4b-738cb9314a6f","type":"Finding","dc:description":"Treatment with the human GUCY2D gene restored proper localization of alpha-transducin (Figs. 3a-3b), which was first reported by PMID: 15623748 to be abnormal in this model. Treatment corrected the defect in scotopic b-wave amplitude by 65-100% (Figs. 4a-4b). Cone amplitude was corrected from 20% of wild-type to 65% of wild-type (Fig. 4c). Similar results were obtained with the mouse Gucy2e transgene (Fig. 5). Head-tracking behavior (measure of visual acuity and contrast sensitivity) was fully corrected by treatment (Fig. 6). Moderate cone preservation was also demonstrated by normalization of alpha-transducin staining, showing a 20% increase in cone numbers relative to the untreated control (Fig. 7r).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21671801","rdfs:label":"Rescue of mouse Gucy2e homozygous knockout by AAV-GUCY2D","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10a9a630-379b-4ceb-810a-e25863524553","type":"EvidenceLine","dc:description":"The ability of GUCY2D to catalyze cGMP production is consistent with the loss of photoreceptor function in patients and the known association between abnormalities in cGMP levels and photoreceptor degeneration.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f3e1656-fad5-45ae-8bf6-234be483b549","type":"Finding","dc:description":"The ability of the exogenously expressed enzyme to efficiently catalyze cGMP production is consistent with the loss of photoreceptor function that is characteristic of the disease, as abnormalities in cGMP levels have long been associated with photoreceptor degeneration (PMID: 4369896).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1356371","rdfs:label":"GUCY2D produces cGMP as a receptor guanylyl cyclase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fd381d1c-b207-49dd-a99c-99f3148317d8","type":"EvidenceLine","dc:description":"This study demonstrates a physical interaction between the mouse orthologs of GUCY2D (cause of LCA1) and RD3 (cause of LCA12) and the requirement for this interaction for proper GUCY2D localization.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a276cb2-13aa-45d1-90e3-907d1b866f22","type":"Finding","dc:description":"Mouse Rd3 was immunoprecipitated by monoclonal antibody and co-purifying proteins were identified by LC-MS/MS. The highest-scoring interacting partner was Gucy2e, the mouse ortholog of GUCY2D (Table S1). This was confirmed by western blotting (Figure 2A) and found to be dependent on the C-terminus of Gucy2e (Figure 5).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21078983","rdfs:label":"GUCY2D protein-protein interaction with RD3","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/019821e5-44ff-4e74-aebe-3bbf738c5a7d","type":"EvidenceLine","dc:description":"The high level of specificity of GUCY2D mRNA expression to the retina (at twice the level of the closest non-retinal tissue) has been used as a rationale to up-score this data from 0.5 to 1 point.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62554d53-5ef9-48c9-9d1a-d448518b8872","type":"Finding","dc:description":"Evidence from the Pan-Tissue Plots feature indicates that the expression of GUCY2D at the mRNA level is far higher in adult retina tissue than in any other tissue type with available RNA-seq data found in the database. GUCY2D expression in adult retina is approximately twice that of the second-highest tissue (testis). An alternative database lacking eye data (GTEx, PMID: 23715323) is compatible with this finding in that it shows GUCY2D levels peaking in the testis (https://gtexportal.org/home/gene/GTEX).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30239781","rdfs:label":"GUCY2D mRNA is highly expressed in human retina","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":4099,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/ddIPQ5Z3MYE","type":"GeneValidityProposition","disease":"obo:MONDO_0100453","gene":"hgnc:4689","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_dcb8350d-c57f-43e3-9e9f-d059ebbf61c9-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}